We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

76 hedge funds and large institutions have $153M invested in KalVista Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

11% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 19

1% more funds holding

Funds holding: 75 → 76 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

11.74% less ownership

Funds ownership: 85.72% → 73.98% (-12%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

53% less capital invested

Capital invested by funds: $328M → $153M (-$175M)

Holders
76
Holders Change
+1
Holders Change %
+1.33%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
15
Increased
21
Reduced
19
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EAM
Eventide Asset Management
Massachusetts
+$2.91M
2
Northern Trust
Northern Trust
Illinois
+$1.69M
3
PAMU
Pictet Asset Management (UK)
United Kingdom
+$1.47M
4
Squarepoint
Squarepoint
New York
+$851K
5
O
OrbiMed
New York
+$626K

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$30.1M
2
DM
Deerfield Management
New York
-$5.28M
3
Invesco
Invesco
Georgia
-$4M
4
ACP
Acuta Capital Partners
California
-$3.04M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.23M
Name Holding Trade Value Shares
Change 		Change in
Stake
SHI
1
SV Health Investors
Massachusetts
$19.9M – – –
EAM
2
Eventide Asset Management
Massachusetts
$19.5M +$2.91M +180,000 +12%
PC
3
Polar Capital
United Kingdom
$16.3M +$262K +16,235 +1%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$10.7M -$833K -51,535 -5%
DM
5
Deerfield Management
New York
$10.3M -$5.28M -327,000 -27%
BlackRock
6
BlackRock
New York
$8.89M +$480K +29,730 +4%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$8.12M – – –
VMI
8
VHCP Management III
New York
$7.4M – – –
PAMU
9
Pictet Asset Management (UK)
United Kingdom
$6.33M +$1.47M +90,989 +20%
Vanguard Group
10
Vanguard Group
Pennsylvania
$6.31M +$262K +16,219 +3%
IVM
11
InterWest Venture Management
California
$4.51M – – –
VMI
12
VHCP Management II
New York
$4.37M – – –
GTC
13
Ghost Tree Capital
New York
$3.65M +$242K +15,000 +5%
State Street
14
State Street
Massachusetts
$2.65M +$441K +27,325 +14%
BC
15
Boxer Capital
California
$2.32M – – –
Northern Trust
16
Northern Trust
Illinois
$2.07M +$1.69M +104,691 +142%
IBT
17
International Biotechnology Trust
United Kingdom
$2.06M -$164K -10,166 -5%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.76M +$160K +9,912 +7%
Dimensional Fund Advisors
19
Dimensional Fund Advisors
Texas
$1.49M +$272K +16,860 +15%
Squarepoint
20
Squarepoint
New York
$1.44M +$851K +52,643 +74%
SB
21
Samsara BioCapital
California
$1.38M – – –
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$1.01M -$1.23M -75,900 -47%
Neuberger Berman Group
23
Neuberger Berman Group
New York
$682K -$90.3K -5,588 -9%
WMSA
24
Weiss Multi-Strategy Advisers
New York
$626K – – –
Goldman Sachs
25
Goldman Sachs
New York
$546K +$423K +26,181 +125%
1
2 3 4

KALV Hedge Fund Activity: Q3 2019 in Review

76 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2019, worth a combined $153M — down 53% from $328M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KALV positions and 14 closed out — a net gain of 1 holder — while 21 added to existing stakes and 19 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $2.91M. The largest seller was Vivo Capital, exiting entirely with an estimated $30.1M sold.

  • 76 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2019, up from 75 in Q2 2019.
  • Funds reported $153M of KalVista Pharmaceuticals stock for Q3 2019, down 53% quarter-over-quarter.
  • 15 funds opened new KalVista Pharmaceuticals positions in Q3 2019 and 14 closed out, a net change of +1 holder.
  • The largest KalVista Pharmaceuticals buyer in Q3 2019 was Eventide Asset Management, an estimated $2.91M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2019 was Vivo Capital, an estimated $30.1M sold.

Based on aggregated 13F filings for Q3 2019.